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Ticagrelor Reduces
Thromboinﬂammatory Markers in
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VISUAL ABSTRACT

HIGHLIGHTS
 As expected, ticagrelor reduced ex-vivo
ADP-induced aggregation in patients with
pneumonia compared with placebo.
 Ticagrelor reduced platelet–leukocyte
interactions as well as plasma interleukin6 within 24 h in patients with pneumonia
compared with placebo.
 Ticagrelor acutely altered NETosis
biomarkers, whereas placebo had no
effect.
 Ticagrelor improved lung function and
reduced need for supplemental oxygen in
patients with pneumonia compared with
placebo.

Sexton, T.R. et al. J Am Coll Cardiol Basic Trans Science. 2018;3(4):435–49.

All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit
the JACC: Basic to Translational Science author instructions page.
Manuscript received April 9, 2018; accepted May 3, 2018.
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SUMMARY

ABBREVIATIONS

Despite treatment advances for sepsis and pneumonia, signiﬁcant improvements in outcome have not been

ADP = adenosine diphosphate

AND ACRONYMS

realized. Antiplatelet therapy may improve outcome in pneumonia and sepsis. In this study, the authors show

CAP = community-acquired

that ticagrelor reduced leukocytes with attached platelets as well as the inﬂammatory biomarker interleukin

pneumonia

(IL)-6. Pneumonia patients receiving ticagrelor required less supplemental oxygen and lung function tests

CI = conﬁdence interval

trended toward improvement. Disruption of the P2Y12 receptor in a murine model protected against inﬂam-

COPD = chronic obstructive

matory response, lung permeability, and mortality. Results indicate a mechanistic link between platelets,

pulmonary disease

leukocytes, and lung injury in settings of pneumonia and sepsis, and suggest possible therapeutic approaches to
reduce complications.(Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor [XANTHIPPE];
NCT01883869) (J Am Coll Cardiol Basic Trans Science 2018;3:435–49) Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND

HAP = hospital-acquired
pneumonia

ELISA = enzyme-linked

license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

S

dsDNA = doubled-stranded
DNA

immunosorbent assay

FEV-1 = forced expiratory
volume in 1 s

epsis is a complex syndrome of dysregulated

mortality and attenuation in thrombocyto-

IL = interleukin

host responses to infection that results in or-

penia (15). More recently, a post hoc analysis

IQR = interquartile range

gan damage and carries a substantial risk of

on the PLATO (Platelet Inhibition and Patient

mortality. Pneumonia is a leading cause of sepsis

Outcomes) trial, in which 18,624 patients

coefﬁcient

and is the most common fatal infection acquired in

presenting with acute coronary syndrome

LPS = lipopolysaccharide

hospitals. Despite advances in treatments, such as

were randomized to receive standard of care

LTA = light transmission

antibiotic therapy and intensive care, signiﬁcant

with the adenosine diphosphate receptor

aggregometry

improvement in mortality rates remains elusive (1).

P2Y 12 antagonist clopidogrel or ticagrelor,

MPO = myeloperoxidase

Additionally, there is increasing awareness of the

which provides stronger and more consistent

MVV = maximum ventilation

burden of cardiovascular complications in patients

P2Y 12 antagonism than clopidogrel, revealed

velocity

hospitalized with pneumonia (2–9). Novel treatment

that ticagrelor was associated with lower

NE = neutrophil elastase

strategies in this high-risk patient population are

mortality in patients with subsequent pul-

NET = neutrophil extracellular

needed.

monary events or sepsis (16). In addition,

trap

In addition to an integral role in hemostasis,

ticagrelor was able to decrease the absolute

OR = odds ratio

platelets contribute to inﬂammatory and immune re-

risk of ischemic events compared with clopi-

PRP = platelet-rich plasma

sponses. Platelets alter properties of endothelial cells

dogrel in patients enrolled in the PLATO trial

TNF = tumor necrosis factor

and leukocytes, release soluble pro- and anti-

that had a history of chronic obstructive pul-

TRAP = thrombin receptor

inﬂammatory mediators, internalize microorganisms,

monary disease (COPD) (17).

and bind and sequester pathogens. Platelet activation

Kfc = capillary ﬁltration

activating peptide

Taken together, these observations sug-

WT = wild-type

and sequestration in pulmonary tissue is a key feature

gest that antiplatelet therapy may improve outcomes

in inﬂammatory or infectious states such as sepsis and

in ambulatory patients with pneumonia, and poten-

acute respiratory distress syndrome (10–12). Recent

tially in sepsis. The mechanism for a beneﬁcial effect

evidence suggests that antiplatelet therapy may

could be multifactorial. Platelet activation is associ-

improve outcomes in patients hospitalized with

ated with worse cardiovascular outcomes in patients

pneumonia. A retrospective, cohort study to evaluate

with pneumonia (2). Platelet activation results in

the effects of antiplatelet therapy on the incidence

adhesion, the expression of cell surface receptors,

and severity of community-acquired pneumonia

and the release of small molecules that can promote

(CAP) reported trends toward reduced instances of

thrombosis and amplify the immune response. Spe-

mechanical ventilation, mortality, and the composite

ciﬁcally, platelet activation results in expression of

endpoint of death in CAP inpatients (13). Similarly, an

P-selectin, increases platelet–leukocyte aggregates,

observational study of 224 hospitalized CAP patients

and triggers the formation of neutrophil extracellular

showed lower use of intensive care unit care in pa-

DNA

tients receiving antiplatelet agents for at least 6

mortality in severe sepsis (18), and DNA nets asso-

months compared with unmatched controls (14). A

ciate with severity of sepsis and septic organ

study of 615 patients consecutively admitted to med-

dysfunction (19). In animals, platelets and neutro-

ical and surgical intensive care units found that use of

phils accumulate in lungs in models of sepsis, during

antiplatelet agents was associated with reductions in

both bacterial and viral infection (20). Furthermore,

nets.

Platelet–leukocyte

aggregates

predict
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T A B L E 1 Inclusion and Exclusion Criteria

T A B L E 2 Baseline Characteristics of XANTHIPPE Subjects

Inclusion criteria
Men or nonpregnant women 18 yrs of age or older

Placebo

Ticagrelor

p Value

Men

14 (47)

13 (43)

1.000

Women

16 (53)

17 (57)

1.000

Age, yrs

55.1  16.0

56.6  15.9

0.705

28 (93)

29 (97)

1.000

2 (7)

1 (3)

1.000

Demographics

Subjects must be willing and able to give informed consent
Diagnosis of CAP or HAP within 48 h of diagnosis or presentation to hospital
Subjects must have new radiographic ﬁnding(s) consistent with pneumonia and at
least 2 of the following signs:
 Cough
 Fever
 Hypothermia
 Purulent sputum production or respiratory secretion
 Total WBC count >10,000/mm 3, or >15% band forms, regardless of total
peripheral white count; or leukopenia with total WBC <4,500/mm 3
 Auscultatory ﬁndings on pulmonary examination of rales and/or evidence
of pulmonary consolidation (dullness on percussion, bronchial breath
sounds, or egophony)
 Hypoxemia
 Increase in dyspnea and/or tachypnea (>20 breaths/min)
Exclusion criteria
Contraindication to ticagrelor (hypersensitivity of reaction to ticagrelor or
another P2Y12 antagonist)

Caucasian
African American
Medical history
Hypertension

15 (50)

23 (77)

0.060

History of smoking

21 (70)

23 (77)

0.771

Diabetes

9 (30)

8 (27)

1.000

COPD

17 (57)

16 (53)

1.000

Aspirin

7 (23)

8 (27)

1.000

P2Y12 inhibitor

4 (13)

7 (23)

0.506

Levoﬂoxacin

8 (27)

14 (47)

0.180

Azithromycin

7 (23)

2 (7)

0.146

Ceftriaxone

5 (17)

5 (17)

Vancomycin

8 (27)

10 (33)

0.779

Levaquin

6 (20)

4 (13)

0.731

Cefepime

3 (10)

4 (13)

1.000

Penicillin

1 (3)

0 (0)

1.000
0.612

Medication on admission

Antibiotics on enrollment

Active or suspected major bleeding history
3

Platelet count <100,000/mm or International normalized ratio >1.5
Surgery within 30 days or anticipated major surgery
Oral anticoagulant that cannot be stopped
Inability or unwillingness of treating physician to reduce dose of aspirin to 100 mg
Fibrinolytic therapy in the last 24 h
Increased risk of bradycardic events—2nd or 3rd degree heart block, bradycardia
induced syncope—unless pacemaker in place

3 (10)

1 (3)

Underlying immunodeﬁciency (HIV, neutropenia, receiving immunomodulating
reagents, active hematologic malignancy, functional or anatomic asplenia,
and hypogammaglobunemia)

Doxycycline

1 (3)

2 (7)

1.000

Peracillin/tazobactam

2 (7)

1 (3)

1.000

Clindamycin

1 (3)

0 (0)

1.000

Concomitant therapy with CYP3A inducer; rifampin/rifampicin, phenytoin,
carbamazepine

Metronidazole

1 (3)

3 (10)

0.612

Pregnancy or lactation
Active treatment for cancer
Acute, decompensated congestive heart failure
Participation in another investigational drug or device study in the last 30 days
Inability to administer enteric medication

Zosyn

1.000

Acyclovir

0 (0)

1 (3)

1.000

Aztreonam

0 (0)

1 (3)

1.000

Values are n (%) or mean  SD. p Values for the qualitative variables were
calculated using Fisher’s exact test. p Values for quantitative variables were
calculated with a 2-sample Student’s t-test.
COPD ¼ chronic obstructive pulmonary disease.

CAP ¼ community-acquired pneumonia; HAP ¼ hospital-acquired pneumonia; WBC ¼ white blood
count.

METHODS AND MATERIALS
PATIENTS AND STUDY DESIGN. XANTHIPPE (Exam-

antiplatelet therapy decreases platelet–leukocyte ag-

ining the effect of Ticagrelor on Platelet Activation,

gregates and reduces lung injury.

Platelet-Leukocyte

Aggregates,

and

Acute

Lung

To explore the possibility that platelets underpin

Injury in Pneumonia is an investigator-designed and

adverse events in pneumonia and sepsis and that

initiated trial) (NCT01883869) was approved by the

potent antiplatelet therapy may attenuate the end-

institutional review board at the University of Ken-

organ or cellular and tissue complications of a dysre-

tucky. All subjects provided written informed consent

gulated immune response, we evaluated the effect of

before participation. The XANTHIPPE trial enrolled

the direct-acting P2Y 12 antagonist ticagrelor on

patients admitted to the University of Kentucky

biomarkers of cardiovascular outcomes in a double-

hospitals with a diagnosis of pneumonia between

blinded,

in

March 26, 2014, and June 10, 2016. Patients were

patients diagnosed with pneumonia. We then per-

enrolled within 48 h of diagnosis of either CAP or

formed

hospital-acquired

placebo-controlled
mechanistic

randomized

studies

of

trial

ticagrelor

on

pneumonia

(HAP),

which

was

endotoxemia-associated mortality in mice. Our ﬁnd-

deﬁned as pneumonia occurring in a patient with any

ings support a role for platelets as a link between

hospital admission in the previous 3 months. Com-

adverse outcomes in pneumonia and sepsis, and

plete inclusion and exclusion criteria can be found in

provide mechanistic insight into potential beneﬁcial

Table 1. Demographics of all enrolled patients are

actions of potent antiplatelet therapy in pneumonia.

presented in Table 2. Patients that were taking a P2Y12
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antagonist upon enrollment were not included on the
analysis

of

ﬂow

cytometry,

platelet

function,

T A B L E 3 Clinical Characteristics of XANTHIPPE Patients

Placebo

biomarker analysis, and spirometry.
The XANTHIPPE trial was a double-blind study in
which subjects were randomized to placebo or ticagrelor (180-mg loading dose followed by 90 mg twice
a day) for up to 7 days or until discharge from the

Ticagrelor

p Value

Pneumonia
CAP

21 (70)

17 (57)

0.422

HAP

9 (30)

13 (43)

0.422
0.094

Blood counts
Baseline platelet count

hospital. Randomization and drug distribution were

248  74

283  85

24-h platelet count

263  94

291  97

0.324

performed by the Investigational Drug Service at the

Baseline WBC

12.04  5.18

12.13  5.83

0.951

University of Kentucky. Blood samples were collected

24-h WBC

10.72  5.10

12.91  6.02

0.183

at baseline just before administration of the loading
dose of study medication and at approximately 24
and 48 h following the initial study dose. An additional blood sample was taken on day of discharge or

Values are n (%) or mean  SD. p Values for the qualitative variables were
calculated using Fisher’s exact test. p Values for quantitative variables were
calculated with a 2-sample Student’s t-test.
Abbreviations as in Table 1.

day 7, whichever came ﬁrst. Study follow-up occurred
daily while admitted to the hospital and at 30 days
after enrollment.
The primary efﬁcacy endpoint of XANTHIPPE was
the change in platelet–leukocyte aggregates (deﬁned
as the percentage of leukocytes with attached platelets) from baseline to 24 h following the initial dose of
study medication. Secondary endpoints included
change in platelet function, change in biomarkers
associated with inﬂammation and thrombosis, and
lung function as determined by bedside spirometry.
Rates of serious adverse events and/or rehospitalization within 30 days of enrollment were determined
by patient follow-up, by clinic or phone call, as well as
by review of electronic medical records.
FLOW

CYTOMETRY. Platelet–leukocyte

plasma (PRP) and whole blood was performed as
previously described (22). Aggregation with PRP prepared from citrated blood was determined using a
light transmission aggregometer (Chrono-log Corp.,
Havertown, Pennsylvania). PRP was incubated at 37 C
for 2 min before treatment with thrombin receptor
activating peptide (TRAP) or adenosine diphosphate
(ADP) to ﬁnal concentrations of 15 mmol/l and 5 m mol/l,
respectively. Maximal aggregation and slope within
the ﬁrst 5 min were calculated using the AGGROLINK
software (Chrono-log Corp.). For multiplate impedance analysis, blood was collected in hirudin tubes
and incubated at 37 C for 3 min before the addition of
agonist. The area under the curve after 6 min of

aggregates

were determined by ﬂow cytometry as previously

agonist was recorded with the Multiplate system
(Roche, Basel, Switzerland). Patients that were taking

described (21). Brieﬂy, fresh whole blood collected in

a P2Y 12 antagonist upon enrollment were excluded

hirudin blood tubes (Diapharma, West Chester, Ohio)

from platelet aggregation analysis.

and incubated with the leukocyte-speciﬁc allophycocyanin

(APC)-conjugated

anti-CD11b/Mac-1

(BD

Biosciences, San Jose, California) and platelet-speciﬁc
ﬂuorescein isothiocyanate (FITC)-conjugated antiCD42b (BD Biosciences) for 15 min at room temperature while protected from light. Samples were ﬁxed
and red blood cells were lysed using FACS Lysing
Solution (BD Biosciences). Flow cytometry was per-

Plasma
from

for

biomarker

analysis

was

collected

citrate-theophylline-adenosine-dipyridamole

(CTAD)-anticoagulated blood that was supplemented
with ethylenediaminetetraacetic acid (EDTA) (ﬁnal
concentration of 10 mmol/l) before centrifugation at
3,000 g for 10 min. Plasma was aliquoted, ﬂash
frozen, and stored at 80 C. Tumor necrosis factor
(TNF)-a , IL-6, IL-1b, IL-10, and sCD40L analytes were

formed at the core facility at the University of Ken-

measured with a MAGPIX multiplex reader using a

tucky. Leukocytes (50,000/gate) were identiﬁed by

Milliplex MAP Kit (Millipore, Burlington, Massachu-

the CD11b-positive signal compared with the isotype

setts). Angiopoietin-1, angiopoietin-2, ELA-2, ENA-78,

control. Platelet–leukocyte aggregates were identiﬁed

NAP-2, and platelet factor (PF)-4 analytes were

by the subset of CD11b-positive cells that were also

measured using DuoSet enzyme-linked immunosor-

CD42b positive as compared with the isotype control.

bent assay (ELISA) kits (R&D Systems, Minneapolis,

FlowJo software version 10 (TreeStar, Ashland, Ore-

Minnesota). Patients taking a P2Y 12 antagonist upon

gon) was used to analyze samples. Patients that were

enrollment were excluded from biomarker analysis.

taking a P2Y 12 antagonist upon enrollment were

Neutrophil extracellular traps (NET) were measured

excluded from analysis.

by ELISA using anti-myeloperoxidase (MPO) (part

PLATELET AGGREGATION AND PLASMA BIOMARKERS.

842842 from R&D Systems) for capture and bio-

Ex vivo platelet aggregation using platelet-rich

tinylated anti-neutrophil elastase (NE) (Ab79962 from

439
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F I G U R E 1 Ticagrelor Reduces Ex Vivo ADP-Induced Platelet Aggregation in Pneumonia Patients

Maximum platelet aggregation was measured by light transmission aggregometry in PRP in response to 5 mmol/l ADP (A) and 15 mmol/l TRAP (C). Area
under the curve values in the Multiplate assay are shown with ADP (B) or TRAP (D) as an agonist. Patients randomized to placebo are represented by open
circles and patients randomized to ticagrelor are represented by ﬁlled circles. A signiﬁcant difference between groups on the change from baseline to 24 h
is indicated by an asterisk. ADP ¼ adenosine diphosphate; AU ¼ arbitrary units; BL ¼ baseline; LTA ¼ light transmission aggregometry; TRAP ¼ thrombin
receptor activating peptide

Abcam, Cambridge, Massachusetts) for detection. MPO

MOUSE STUDY. Mice deﬁcient in P2Y 12 were gener-

and NE are in complex with chromatin in NETs. Sam-

ated as described previously (24). Littermate wild-

ples were calibrated to a serial dilution of serum and

type (WT) mice from heterozygous breeding were

assigned arbitrary units based on detected signal.

used as controls. The mice were bred and maintained

Quant-iT Picogreen kits (Thermo Fisher Scientiﬁc,

in the University of Kentucky Animal Care Facility

Waltham, Massachusetts) were used to measure

following institutional and National Institutes of

doubled-stranded DNA (dsDNA) in plasma.

Health guidelines after approval by the Animal Care

SPIROMETRY. Spirometry was performed following

Committee.

American

Thoracic

Society/European

Respiratory

WT and P2ry12 / male mice (8 to 10 weeks of age)

Society guidelines (23) at the patient bedside using

were fed placebo, clopidogrel (25 mg/kg body weight

a CareFusion MicroLoop spirometer (Vyaire Medical,

per 24 h), or ticagrelor (10, 25, 50 mg/kg body weight,

Mettawa,

forced

per 12 h) by oral gavage. Two h later, the animals were

velocity

injected intraperitoneally with lipopolysaccharide

(MVV) were performed at baseline (before drug

(LPS) (0111:B4, 10 mg/kg in 200 m l, Sigma Aldrich, St.

randomization), 24 h after dosage, and day of

Louis, Missouri). Mice were assessed every 12 h for 5

discharge on subjects that were able and willing to

days. Blood was collected at the indicated time points

perform.

after LPS injection, and plasma was prepared by

spirometry,

Illinois).
and

Relaxed

maximum

spirometry,
ventilation
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centrifugation. TNF-a and IL-6 were measured by
ELISA assay (eBioscience, San Diego, California).

F I G U R E 2 Ticagrelor Reduces Platelet–Leukocyte Aggregates

DETERMINATION OF PULMONARY MICROVASCULAR
PERMEABILITY. Lungs were isolated 6 h after injec-

tion of LPS and microvessel capillary ﬁltration coefﬁcient (K fc) was measured as described previously
(23). In brief, after 20-min equilibration perfusion to
establish an isogravimetric condition, the outﬂow
pressure was rapidly elevated by 10 cm of H2O for 20
min. In response to the pressure increase, lung
preparations gained weight due to net ﬂuid accumulation. Lungs were dissected free of nonpulmonary
tissue, and lung dry weight was determined. Kfc was
calculated from the slope of the weight change
normalized to the pressure change and lung dry
weight.
STATISTICAL ANALYSES. Baseline and clinical char-

acteristics in Tables 2 and 3 were compared between
the 2 groups using Student’s t-test and Fisher’s exact
test. For the repeated-measures data in the platelet
aggregation, platelet–leukocyte aggregate assays, and
for non-IL biomarkers (sCD40L, TNF- a , ENA-78, NAP2, and PF-4), we ﬁtted a linear mixed-effects model to
compare groups at day 1, at day 2, and on change from
day 1 to day 2. Logarithmic transformation was
applied to some non-normally distributed data. For
the IL-6, IL-10, and IL-1b biomarkers, we compared
groups at day 1, at day 2, and on change from day 1 to
day 2 using Mann-Whitney rank sum tests. Linear
regression was used to determine the relationship
between baseline platelet–leukocyte aggregates and
change at 24 h. For comparison of baseline biomarkers of treatment groups to healthy controls, a
Mann-Whitney rank sum test was used. The MPO-NE
assay measurements were non-normally distributed
with some negative values so a logarithmic transformation was inappropriate. To contrast MPO-NE
assay measurements between the ticagrelor group
and the placebo group, we used non-parametric rank
sum tests with a Bonferroni correction for multiple

The percentage of leukocytes with attached platelets for each subject is plotted at
baseline (BL) and at 24 h in patients given placebo (A, open circles) and ticagrelor
(A, ﬁlled circles). A signiﬁcant difference between groups on the change from baseline to
24 h is indicated by an asterisk. Delta change of platelet–leukocyte aggregates at 24 h

comparisons. The Picogreen assay measures were

(compared with baseline) is represented for patients randomized to placebo (B, open

analyzed using the parametric mixed-modelling

circles and top dashed line) and ticagrelor (B, ﬁlled circles and bottom dashed line).

approach with unstructured covariance and a Tukey
correction for multiple comparison. To assess the effects of ticagrelor on lung function, for each patient,

continuous response variable, we performed a 1-way

we ﬁrst computed differences between baseline and

analysis of variance. Relationships between mortal-

24-h lung function measurements and then con-

ity and P2Y12 antagonists were analyzed using the log-

trasted mean lung function differences between the

rank test. To explore the role of P2Y 12 receptor in mice

ticagrelor group and the placebo group by a 2-sample

treated with either a placebo or with the P2Y12 an-

Student’s t-test with unequal variances. To evaluate

tagonists (ticagrelor or clopidogrel), Cox proportional

the effects of P2Y 12 antagonists across doses as well as

hazards models were employed. To examine whether

changes

over

time,

appropriate

contrasts

were

P2Y 12 antagonism (ticagrelor or clopidogrel) affects

considered. For multiple group comparison with a

pulmonary microvascular permeability, K fc were
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T A B L E 4 Biomarkers

Ticagrelor
Healthy Plasma

NAP-2

Day 1

295 (228–333)

ENA-78

291 (156–533)

52.55 (40.42–64.38)

Placebo
Day 2

Day 1

355 (213–676)

48.9 (32.8–87.5)

50.0 (39.8–102.5)

PF-4

273 (224–325)

225 (119–339)

232 (136–419)

IL-10

3.08 (1.81–4.17)

3.76 (0.00–16.38)

4.40 (1.70–16.35)

Day 2

148 (95–404)

186 (115–337)

39.4 (31.0–76.2)

46.2 (35.7–73.6)

248 (121–360)

291 (179–362)

4.67 (1.39–20.59)

3.15 (0.00–35.28)
9.93 (2.00–37.33)†

IL-6

0.82 (0.77–2.03)

19.25 (3.20–42.52)*

3.20 (1.80–14.19)*

8.53 (0.99–17.74)*

TNF-a

6.86 (4.66–8.08)

8.02 (4.19–18.69)

9.36 (5.76–23.02)

9.98 (5.62–16.66)

8.76 (6.40–21.44)

IL-1b

0.64 (0.42–0.86)

0.60 (0.04–2.30)

1.00 (0.28–2.44)

0.62 (0.00–2.93)

0.62 (0.00–7.54)

111.6 (50.0–255.4)

140.2 (81.0–239.6)

95.5 (53.5–211.5)

142.3 (66.4–217.5)

sCD40L

57.2 (35.03–77.61)

Values are median (interquartile range) in pg/ml. *Day 1 value is signiﬁcantly different from healthy plasma (Mann-Whitney rank sum test). †Signiﬁcant difference between the 2
treatment groups in the change from baseline to 24 h (linear mixed modeling or Mann-Whitney rank sum test).

contrasted using 1-way analysis of variance with a

maximum ADP- and TRAP-induced platelet aggrega-

Tukey adjustment for multiple comparison. Statisti-

tion were similar in the 2 groups (Figure 1). At 24 h,

cal analysis was executed on SAS versions 9.3 and 9.4

patients randomized to ticagrelor had lower ADP-

(SAS Institute, Cary, North Carolina), SigmaPlot

induced aggregation as measured by light trans-

version 13.0 (Systat Software, San Jose, California)

mission aggregometry [LTA] (Figure 1A) and multiple

and

Statistical

electrode impedance assay (Figure 1B). No signiﬁcant

Computing, Vienna, Austria). Graphs in ﬁgures were

differences were observed between the groups at 24 h

generated in SigmaPlot version 13.0.

in aggregation induced by the PAR1 agonist TRAP by

R

version

3.2.3

(R

Project

for

LTA (Figure 1C) or multiple electrode impedance assay

RESULTS

(Figure 1D). Consistent with the effects of ticagrelor,
the change in ADP-induced aggregation from baseline

TICAGRELOR

MODULATES

INFLAMMATORY

to 24 h was signiﬁcantly different between subjects

WITH

assigned to placebo and ticagrelor (p ¼ 0.0065 [LTA]

PNEUMONIA. To evaluate the effect of the direct

and p < 0.0001 [impedance assay]). No signiﬁcant

acting P2Y 12 antagonist ticagrelor in pneumonia, we

difference was noted for TRAP-induced aggregation

randomized patients hospitalized within 48 h of

(p ¼ 0.1283 [LTA] and p ¼ 0.2937 [impedance assay]).

RESPONSE

IN

PATIENTS

HOSPITALIZED

diagnosis to receive placebo or ticagrelor for up to 7

Local inﬂammatory events mediated by leukocytes

days. Table 2 lists demographic and baseline charac-

and platelets have been proposed to underlie acute

teristics of patients enrolled in the XANTHIPPE trial.

lung injury, and circulating platelet–leukocyte het-

The average age was 55.1  16.0 years in the placebo

erotypic cell aggregates increase in animal models of

group (53% female) and 56.6  15.9 years in the tica-

lung injury (25). Therefore, we determined whether

grelor group (57% female). There were no signiﬁcant

ticagrelor altered platelet–leukocyte aggregates in

differences in history of hypertension, smoking his-

patients with pneumonia. No difference in platelet–

tory, diabetes, and COPD between the 2 groups. There

leukocyte

was no signiﬁcant difference between the 2 groups

groups was present at baseline (Figure 2A). Between

with regard to aspirin use before enrollment. There

baseline and 24 h after drug administration, a sig-

were no signiﬁcant differences in antibiotic treatment

niﬁcant difference in the change in heterotypic cell

at the time of enrollment between the 2 groups.

aggregates was observed in the placebo and ticagrelor

Twenty-one subjects were diagnosed with CAP in the

groups (p ¼ 0.0244). The percentage of leukocytes

aggregates

in

placebo

and

ticagrelor

placebo arm (70%) and 17 subjects in the ticagrelor

with attached platelets declined from a median of

arm (57%) (Table 3). At 30 days, there were a total of 7

49.65% (interquartile range [IQR]: 36.00% to 55.73%)

rehospitalizations (4 in the placebo group and 3 in the

at baseline to 37.90% (IQR: 23.93% to 46.35%) at 24 h

ticagrelor group) and 3 deaths (3 in the placebo group

after ticagrelor; whereas in subjects randomized to

and 0 in the ticagrelor group). No major bleeding

placebo, the median percentage of leukocytes with

occurred in any of the patients.

attached platelets was 41.30% (IQR: 31.35% to

No signiﬁcant differences in platelet or white blood

60.85%) at baseline and increased to 52.20% (IQR:

cell counts were observed in the 2 groups at baseline

40.40% to 66.30%) at 24 h. Interestingly, the magni-

or at 24 h after intervention (Table 3). At baseline,

tude of the response to ticagrelor depended on the
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percentage of leukocytes with attached platelets at
baseline,

with

larger

responses

to

ticagrelor

F I G U R E 3 Ticagrelor and NETosis Biomarkers in Pneumonia Patients

(Figure 2B) observed in individuals with more
platelet–leukocyte aggregates at baseline.
The effects of ticagrelor on other markers of
platelet activation and systemic plasma biomarkers of
inﬂammation were examined next. sCD40 ligand is
released from the platelet membrane during activation. Baseline plasma sCD40L levels in both the placebo and ticagrelor groups were similar to levels in
healthy controls and increased at 24 h irrespective of
randomization arm (Table 4). Of a series of inﬂammatory biomarkers, including IL-6, TNF-a , IL-1b,
IL-10, NAP-2, and ENA-78, only IL-6 was above
normal levels at baseline in the 2 groups. From
baseline to 24 h, IL-6 levels changed signiﬁcantly
differently in the placebo and ticagrelor groups
(p ¼ 0.0226). In subjects randomized to ticagrelor,
median plasma IL-6 levels declined by 83% from
19.25 pg/ml at baseline to 3.20 pg/ml at 24 h.
No decrease was observed in the placebo group,
which had plasma IL-6 levels of 8.53 pg/ml at baseline
and 9.93 pg/ml at 24 h after randomization.
Platelets may also contribute to the formation of
NETs, protein-DNA complexes released from neutrophils that contain MPO and NE in complex with
chromatin. NETs facilitate pathogen clearance; however, their presence has also been associated with
sepsis and sepsis organ dysfunction. We therefore
measured the levels of MPO-NE complexes as a
marker of NETosis in XANTHIPPE patients up to 48 h
after placebo or ticagrelor. Somewhat surprisingly,
relative to the baseline values, a signiﬁcant increase
in MPO-NE complexes was observed at 24 h (p ¼
0.0410) in the ticagrelor group. No signiﬁcant change

The delta change at 24 and 48 h after dosing for the MPO-NE NETosis assay (A) and

occurred in the placebo group (Figure 3A). Circulating

circulating dsDNA (B) were measured in placebo patients (open circles) and ticagrelor

ds-DNA quantiﬁed by the PicoGreen assay (Thermo

patients (ﬁlled circles) that had samples through 48 h after dosing. Signiﬁcant changes

Fisher Scientiﬁc), did not signiﬁcantly change at 24 h
after treatment in either group (Figure 3B), although a

are indicated by an asterisk. dsDNA ¼ doubled-stranded DNA; MPO ¼ myeloperoxidase;
NE ¼ neutrophil elastase.

near-signiﬁcant reduction in dsDNA occurred in the
ticagrelor group at 48 h after therapy (p ¼ 0.0511).
The effects of ticagrelor on lung function and

mean increase of 0.185 l in forced expiratory volume
in 1 s (FEV-1) at 24 h, as compared with a mean 0.057-l

supplemental oxygen requirements were assessed,

change in placebo patients (Figure 4B). Finally, MVV

respectively, by bedside spirometry on patients

decreased on an average by 1.51 l/min at 24 h in

willing and able to perform the test and by patient

ticagrelor patients, whereas MVV in the placebo

records. In patients not receiving a P2Y 12 antagonist

group increased by 2.31 l/min (Figure 4C). However,

at baseline, 10 of the patients randomized to tica-

none of the differences between ticagrelor-treated

grelor and 13 randomized to placebo were able to

patients and the placebo group were statistically

perform spirometry tests at both baseline and 24 h. In

signiﬁcant (change in tidal volume p value ¼ 0.187,

patients receiving ticagrelor, the mean tidal volume

change in FEV-1 p ¼ 0.387, change in MVV p ¼ 0.447).

increased by 0.205 l from baseline to 24 h, whereas

Ticagrelor patients did, however, have a signiﬁcant

the change in the placebo group was only 0.008 l

reduction away from supplemental oxygen (odds ra-

(Figure 4A). The ticagrelor group also displayed a

tio [OR]: 1.08, 95% conﬁdence interval [CI]: 1.01 to

443

444

Sexton et al.

JACC: BASIC TO TRANSLATIONAL SCIENCE VOL. 3, NO. 4, 2018
AUGUST 2018:435–49

Ticagrelor in the Setting of Pneumonia and Sepsis

F I G U R E 4 Ticagrelor and Lung Function Within 24 h in Pneumonia Patients

1.15) compared with no change in placebo patients
(OR: 0.99; 95% CI: 0.95 to 1.04) (Figure 5).
P2Y 1 2

RECEPTOR

FUNCTION

MODULATES

RESPONSE IN ACUTE INFLAMMATORY PRECLINICAL
MODELS. Our results indicate that ticagrelor has ef-

fects on systemic biomarkers of inﬂammation in patients with pneumonia. To explore the role of P2Y12
receptor function in an acute inﬂammatory model,
mice were treated with placebo, ticagrelor, or clopidogrel before intraperitoneal LPS (10 mg/kg). Within
hours of LPS administration, plasma inﬂammatory
and anti-inﬂammatory cytokine levels increased. At 1
h in WT mice, plasma TNF- a levels were approximately 20-fold higher than baseline (Figure 6A).
Ticagrelor treatment at all doses reduced TNF-a at 1 h,
but this decrease was statistically signiﬁcant only for
25 mg/kg dose (p < 0.01). Over longer times (2 to 8 h),
ticagrelor had no signiﬁcant effect on reducing TNF-a
levels (Figure 6A). Ticagrelor elicited an increase in
IL-10 levels after LPS. At higher doses (25 and 50 mg/
kg), but not the lower dose (10 mg/kg), ticagrelortreated mice had increased IL-10 at all time points
compared with controls (p < 0.05 for all treatment
doses and times, except ticagrelor dose 50 mg/kg at
4 h; p ¼ 0.06) (Figure 6B). Clopidogrel had no signiﬁcant effect on TNF- a , but IL-10 levels were
elevated at 2 h and 8 h (p < 0.05 for both time
points).
In comparison to WT controls, mice lacking the
P2Y12 receptor (P2ry12/) were protected from death
from endotoxemia (p < 0.001) (Figure 6C). Ticagrelor,
but not clopidogrel, conferred protection in WT animals (p < 0.05) (Figure 6D) without an additive effect
in the P2ry12 / background.
Endotoxemia causes an inﬂammatory reaction,
associated with disruption in endothelial barrier
function, enhanced permeability, and the development of tissue edema. In the lung, this can manifest
as acute lung injury. To examine whether P2Y12
antagonism affects pulmonary microvascular permeability, Kfc was measured in isolated perfused lung
preparations. Lungs from mice pre-treated with ticagrelor at higher doses (25 and 50 mg/kg) displayed
Lung function was tested in subjects willing and able to undergo spirometry
testing. Data were collected at baseline and at 24 h. Changes at 24 h from
baseline (midline in all 3 graphs) are shown for tidal volume (A), FEV-1 (B), and

lower Kfc after LPS treatment (p < 0.05) (Figure 6E),
suggesting that ticagrelor reduced LPS-induced pul-

MVV (C). Units reported are liters for tidal volume and FEV-1 (A, B) and liters

monary capillary permeability. Conversely, ticagrelor

per minute for MVV (C). Data from patients randomized to placebo are

at a lower dose (10 mg/kg) and clopidogrel did not

shown in the open boxes, whereas patients randomized to ticagrelor are

yield a statistically signiﬁcant reduction in Kfc levels.

represented in the shaded boxes. Each box represents the interquartile range
(25% to 75%), whereas the whiskers represent the full range of the data. The
vertical line in each interquartile range box represents the median value

Taken together, our ﬁndings in a preclinical model
indicate that ticagrelor can attenuate inﬂammation

(note that the median for the placebo group in C overlaps with the midline).

and may protect against inﬂammation-associated

FEV-1 ¼ forced expiratory volume in 1 s; MVV ¼ maximum ventilation velocity.

acute lung permeability, which could have a beneﬁt
in patients with pneumonia.
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F I G U R E 5 Pneumonia Patients Taking Ticagrelor Became Less Reliant on Supplemental Oxygen

Supplemental oxygen requirements were recorded from patient records. Data were collected at the time closest to when the patient received
the study medication and 24 and 48 h following study dosage. Supplemental oxygen was recorded as none (room air), nasal cannula, and
high-ﬂow (HF) devices and mechanical ventilation. Patients randomized to ticagrelor demonstrated a progression to room air and away from
supplemental oxygen (odds ratio [OR]: 1.08; 95% conﬁdence interval [CI]: 1.01 to 1.15). Patients randomized to placebo did not change over
48 h after receiving the study dose (OR: 0.99; 95% CI: 0.95 to 1.04).

DISCUSSION

elevation of IL-10 exclusively occurred at 25 and 50
mg/kg doses of ticagrelor and not at the lower 10

Pneumonia is one the most common causes of death

mg/kg dose indicating a threshold concentration of

from infectious diseases worldwide. Left untreated, it

ticagrelor must be achieved in order to elicit an anti-

can lead to serious complications such as acute lung

inﬂammatory effect. Furthermore, there seems to be

injury and sepsis. Sepsis, a complex and poorly un-

a ceiling to IL-10 increase because we did not

derstood condition, carries a high mortality rate, and

observe higher levels in the 50 mg/kg dose compared

current treatments are generally supportive. Here, we

with the 25 mg/kg dose. Moreover, animals pre-

identify the platelet P2Y12 receptor as a potential target

treated with ticagrelor or lacking P2Y12 receptors

to prevent the complications of sepsis and for reducing

were more likely to survive endotoxemia. Inﬂam-

lung injury, and suggest that the P2Y12 antagonist

mation and infections have been associated with

ticagrelor may be of clinical beneﬁt in the treatment

platelet activation and platelet–leukocyte hetero-

of pneumonia. Taken together, these ﬁndings support

typic aggregate formation. Ticagrelor administration

a novel mechanism to prevent life-threatening com-

to

plications of pneumonia and may explain the mortality

leukocyte aggregates in circulation and lowered IL-

patients

with

pneumonia

reduced

platelet–

beneﬁt observed in patients randomized to ticagrelor

6 levels, consistent with an anti-inﬂammatory ef-

in the PLATO trial (26).

fect. Given that platelet–leukocyte aggregates serve

Ticagrelor, but not clopidogrel, attenuated the

as a sensitive in vivo marker of platelet activation,

inﬂammatory response to LPS in mice by blunting

and increase from a mean of approximately 19% to

the increase in TNF-a and elevating IL-10 levels. The

34% in patients presenting with acute myocardial
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F I G U R E 6 Ticagrelor Reduces Inﬂammation, Increases Lung Function, and Protects Against Mortality in a Murine Sepsis Model

The concentrations of TNF-a (A) and IL-10 (B) at 0 h up to 8 h post-LPS injection are graphed for control mice and mice treated with ticagrelor or
clopidogrel (A and B, reported as mean with bar indicating SE). Signiﬁcant difference over the time course compared with the control is indicated
by an asterisk in A and B. Survival curves of wild-type (WT) mice and P2y12/ mice injected with LPS are plotted in C, whereas D shows survival
curves of WT and P2y12/ mice treated with clopidogrel or ticagrelor (T10) before LPS injection. Signiﬁcance between mutant and WT (A) and
P2Y12 antagonist treated and untreated (D) is indicated by an asterisk. Capillary ﬁltration coefﬁcients (KFC) are graphed for control mice and
mice treated with ticagrelor or clopidogrel (E, reported as mean with bar indicating SE). Signiﬁcant differences between treatment group and
control are indicated by an asterisk. IL ¼ interleukin; LPS ¼ lipopolysaccharide; TNF ¼ tumor necrosis factor.
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infarction, the differences observed with ticagrelor

disruptions in integrity, and they may also be affected

likely reﬂect a meaningful effect of platelet activa-

in

tion in pneumonia. These anti-inﬂammatory effects

platelets with leukocytes in pulmonary tissue is a key

pneumonia-type

infections.

Sequestration

of

of P2Y 12 antagonism are consistent with those

feature in inﬂammatory or infectious states (35).

observed in a rat model of LPS-induced sepsis in

Activated platelets alone or neutrophil–platelet ag-

which pre-treatment with clopidogrel reduced IL-6

gregates may occlude small pulmonary vessels to

and TNF- a (27), as well as a mouse model of

perpetuate local inﬂammation or line the endothe-

sepsis and acute lung injury in which clopidogrel-

lium to contribute to leakage of plasma and cellular

treated

to

components across a normally impermeable barrier

anti-

into the alveolar and interstitial spaces of the lung.

inﬂammatory effects of P2Y12 are also consistent

Through these and other mechanisms, platelet–

with retrospective clinical studies in which anti-

leukocyte interactions can disrupt lung endothelial

platelet drugs had a favorable effect on patients with

barrier function in sepsis and acute respiratory

organ

CAP

distress syndrome (11,36). Our results suggest that

(14,15,29). However, in all of those studies, there was

potent P2Y 12 antagonism with ticagrelor can interrupt

no beneﬁt of clopidogrel on mortality. Here, we

key molecular signaling pathways responsible for

demonstrate, not only an anti-inﬂammatory effect of

lung permeability.

and

P2Y 12-null

sepsis-induced

lung

dysfunction

mice

injury

(such

were
(28).

as

resistant
These

sepsis)

and

ticagrelor apparently equal to or greater than that of

In this work, we have shown both murine and

clopidogrel, but also improvement on survival in

clinical measures that suggest improved lung func-

LPS-treated mice. As a potent, direct-acting P2Y12

tion during sepsis and pneumonia following treat-

antagonist, ticagrelor may be particularly well suited

ment with ticagrelor. Furthermore, we observed a

to reduce adverse events mediated by platelets in

baseline-dependent effect of ticagrelor on circu-

the setting of inﬂammation. In the setting of acute

lating platelet–leukocyte aggregates following tica-

coronary syndrome, patients taking clopidogrel have

grelor treatment in pneumonia patients, although

high on-treatment platelet reactivity that can be

this observation could be due, in part, to regression to

overcome with ticagrelor (30,31). Although not yet

the mean. Patients with higher baseline platelet-

reported, a similar phenomenon may occur in other

leukocyte aggregates also had greater reductions in

inﬂammatory

and

platelet-leukocyte aggregates following ticagrelor

sepsis. Additionally, by inhibiting the adenosine

treatment. These reductions in platelet–leukocyte

transport ENT1, ticagrelor may have adenosine-

aggregates could possibly explain the improvements

mediated effects that could promote vasodilation,

observed in lung function in both our animal and

platelet inhibition, and modulate inﬂammation (32).

human models.

settings

such

as

pneumonia

Although work in our lab has traditionally focused

STUDY LIMITATIONS. The XANTHIPPE study was a

on anti-inﬂammatory effects by reducing platelet–

prospective study designed to target pneumonia

leukocyte interactions, there is some evidence from

patients. Due to a combination of pneumonia pa-

translational work that these platelet–leukocyte in-

tients having the capacity to consent as well as

teractions can be beneﬁcial. In a study by Tunjung-

exclusion criteria, the recruited population was less

putri et al. (33), pro- and anti-inﬂammatory effects

sick than we had anticipated. We also acknowledge

of ticagrelor were observed in blood exposed to

that cecal ligation and puncture model of sepsis may

Pam3CSK4

carry more clinical relevance than the endotoxin

(TLR2-mediated)

and

LPS

(TLR4-

mediated), respectively. Interestingly, in a study

model that was employed; however, the inﬂamma-

investigating the effectiveness of the P2Y12 antago-

tory response to sepsis and the anti-inﬂammatory

nist prasugrel in reducing coagulation and inﬂam-

effects of ticagrelor are likely similar between the 2

mation in a human LPS model, prasugrel had no

models.

effect on platelet–leukocyte aggregation (34). Thus,
it is possible that ticagrelor has unique effects on
platelet–leukocyte interactions.
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During sepsis, endothelial dysfunction leads to

Smyth, Gill Heart and Vascular Institute, 741 South

systemic capillary leak and multiple-organ failure.

Limestone, University of Kentucky, BBSRB B345, Lex-

The pulmonary microvessels are especially prone to

ington, Kentucky 40536. E-mail: ssmyt2@uky.edu.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Ticagre-

extend well beyond hemostasis. In this work, the authors

lor is commonly used in patients with acute coronary

demonstrate that targeting the platelet P2Y12 receptor

syndrome. This work indicates a potential use for tica-

reduces platelet–leukocyte interactions, alters inﬂamma-

grelor to target inﬂammation and improve lung function

tory biomarkers, and can improve lung function in the

in the setting of pneumonia. The ﬁndings suggest the

context of pneumonia and in experimental models of

possibility that ticagrelor could prevent complications of

sepsis. Preclinical models should provide additional

sepsis, although larger-scale clinical studies are required.

mechanistic insight into the beneﬁts of antiplatelet
therapy beyond preventing the complications of athero-

TRANSLATIONAL OUTLOOK: Over the last decade, it

sclerotic disease.

has become clear that platelets play vital roles that
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